Coherus Oncology, Inc. (CHRS) Operating income 2016–2025
Coherus Oncology, Inc. (CHRS) annual operating income history from SEC filings — each fiscal year as reported.
-$181.1MFY2025 · since FY2016: -$115.9M → -$181.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$181.1M | +9.3% |
| FY2024 | -$199.7M | +1.7% |
| FY2023 | -$203.2M | +20.9% |
| FY2022 | -$256.9M | +2.6% |
| FY2021 | -$263.9M | -268.8% |
| FY2020 | $156.3M | +45.1% |
| FY2019 | $107.8M | +152.7% |
| FY2018 | -$204.4M | +11.9% |
| FY2017 | -$232.1M | -100.2% |
| FY2016 | -$115.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More CHRS financial trends
CHRS RevenueCHRS Net incomeCHRS Net marginCHRS Gross profitCHRS Gross marginCHRS Operating marginCHRS Operating cash flowCHRS Free cash flowCHRS Capital expendituresCHRS Return on equityCHRS Stock buybacksCHRS Dividends paidCHRS Total assetsCHRS Total liabilitiesCHRS Shareholders’ equityCHRS overview →